FindTrial
Sign In

Effect of Ramipril on Diabetic Autonomic Neuropathy in Type II Diabetes Mellitus

Comparative evaluation of Effect of Ramipril on Diabetic Autonomic Neuropathy in patients with Type II Diabetes Mellitus: A prospective, randomized, placebo controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024723
Enrollment
50
Registered
2020-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: Tablet Ramipril 2.5 mg: Tablet Ramipril 2.5 mg once a day orally for 12 months Control Intervention1: Placebo: Tab placebo once a day orally for 12 month

Sponsors

Dr Chaitali Chindhalore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient of either gender 2. Age between 30-70 years 3. Suffering from type II DM 4. Duration of disease less than 5 years 5. Derranged autonomic functions test as detected by various tests.

Exclusion criteria

Exclusion criteria: 1. Patients with associated hypertension, 2. Patients who are already on ACEI, 3. Beta blockers or 4. aldose reductase inhibitor 5. Patients with altered KFT 6. Pregnant & lactating women

Design outcomes

Primary

MeasureTime frame
1. Changes in cardiovascular autonomic reactivity parameters in patients 2. Parameter of autonomic activity (HRV) in type II Diabetic patientsTimepoint: at the end of 6 months and 1 year—

Secondary

MeasureTime frame
Parameter of autonomic activity (HRV) in type II Diabetic patientsTimepoint: At the end of 6 months and 1 year—

Countries

India

Contacts

Public ContactDr Chaitali Chindhalore

All India Institute of Medical Sciences, Nagpur

chaitali_bajait@yahoo.com8999905594

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026